U.S. flag

An official website of the United States government

NM_000023.4(SGCA):c.1015G>A (p.Gly339Arg) AND not provided

Germline classification:
Uncertain significance (2 submissions)
Last evaluated:
Jun 18, 2021
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000406824.6

Allele description [Variation Report for NM_000023.4(SGCA):c.1015G>A (p.Gly339Arg)]

NM_000023.4(SGCA):c.1015G>A (p.Gly339Arg)

Gene:
SGCA:sarcoglycan alpha [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q21.33
Genomic location:
Preferred name:
NM_000023.4(SGCA):c.1015G>A (p.Gly339Arg)
HGVS:
  • NC_000017.11:g.50175288G>A
  • NG_008889.1:g.14284G>A
  • NM_000023.4:c.1015G>AMANE SELECT
  • NM_001135697.3:c.643G>A
  • NP_000014.1:p.Gly339Arg
  • NP_001129169.1:p.Gly215Arg
  • LRG_203t1:c.1015G>A
  • LRG_203:g.14284G>A
  • NC_000017.10:g.48252649G>A
  • NM_000023.2:c.1015G>A
  • NM_000023.3:c.1015G>A
  • NR_135553.2:n.842G>A
Protein change:
G215R
Links:
dbSNP: rs540254057
NCBI 1000 Genomes Browser:
rs540254057
Molecular consequence:
  • NM_000023.4:c.1015G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001135697.3:c.643G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NR_135553.2:n.842G>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]
Observations:
1

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000334565Eurofins Ntd Llc (ga)
criteria provided, single submitter

(EGL Classification Definitions 2015)
Uncertain significance
(Aug 25, 2015)
germlineclinical testing

Citation Link,

SCV002771317Athena Diagnostics
criteria provided, single submitter

(Athena Diagnostics Criteria)
Uncertain significance
(Jun 18, 2021)
unknownclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown1not providednot providednot providednot providedclinical testing
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders.

Karbassi I, Maston GA, Love A, DiVincenzo C, Braastad CD, Elzinga CD, Bright AR, Previte D, Zhang K, Rowland CM, McCarthy M, Lapierre JL, Dubois F, Medeiros KA, Batish SD, Jones J, Liaquat K, Hoffman CA, Jaremko M, Wang Z, Sun W, Buller-Burckle A, et al.

Hum Mutat. 2016 Jan;37(1):127-34. doi: 10.1002/humu.22918. Epub 2015 Oct 29.

PubMed [citation]
PMID:
26467025
PMCID:
PMC4737317

Details of each submission

From Eurofins Ntd Llc (ga), SCV000334565.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot provided1not providednot providednot provided

From Athena Diagnostics, SCV002771317.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024